title: Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
abstract: Efficiency and safety of amantadine sulfate (AMS) infusions were investigated in late stage complications of Parkinson's disease (PD). In an open-label study, 21 PD patients suffering from motor fluctuations and/or dyskinesias were administered AMS infusions (PK-Merz, 400 mg per day) during seven days. Oral AMS treatment followed. Significant improvement of UPDRS motor scores was observed between day 0 and day 7, remaining improved until day 21. Based on patients' diary notes, both severity and occurrence of hypokinetic "off" state significantly decreased (from 6.6 to 3.1 hours, p < 0.001, average "off" time per day) as well as dopaminergic-induced dyskinesias (from 2.5 to 1.3 hours, p < 0.05, average duration of dyskinesias per day). AMS infusions followed by oral administration appeared as a safe method for improvement of both motor fluctuations and dyskinesias in advanced PD. In advantage to simple oral therapy, AMS infusions allowed fast introduction of a profound and durable treatment effect.
authors.affiliation: Movement Disorder Center, Department of Neurology, 1st Medical Faculty, Charles' University and General Teaching Hospital, Prague, Czech Republic. ruzicka@tremor.anet.cz
authors.forename: E
authors.initials: E
authors.lastname: Růzicka
authors.forename: H
authors.initials: H
authors.lastname: Streitová
authors.forename: R
authors.initials: R
authors.lastname: Jech
authors.forename: P
authors.initials: P
authors.lastname: Kanovský
authors.forename: J
authors.initials: J
authors.lastname: Roth
authors.forename: I
authors.initials: I
authors.lastname: Rektorová
authors.forename: P
authors.initials: P
authors.lastname: Mecír
authors.forename: H
authors.initials: H
authors.lastname: Hortová
authors.forename: M
authors.initials: M
authors.lastname: Bares
authors.forename: B
authors.initials: B
authors.lastname: Hejduková
authors.forename: I
authors.initials: I
authors.lastname: Rektor
mesh_terms: D000284:Administration, Oral; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D012449:Safety; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D000547:Amantadine